Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

AbbVie announces $250M acquisition of biotech company Celsius Therapeutics

Jun 28, 2024

On 28 June 2024, AbbVie announced its acquisition of Celsius Therapeutics, a privately owned biotech firm developing treatments for patients suffering from inflammatory diseases. This includes  CEL383, an anti-TREM1 antibody which has successfully completed a Phase 1 clinical trial for treating IBD. 

This news follows AbbVie’s announcement in January 2024 that it is investing US$223M in expanding its biologics manufacturing facility in Singapore.